Endometrial cancer trials in Spain

In Spain 53 Also abroad 395

53 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Where
A Coruña, Barcelona, Córdoba, Donostia, Girona, Jaén, L'Hospitalet de Llobregat, Madrid, Palma, Valencia
Age
18 years and over
People
480 worldwide
Run by
BioNTech SE
See details and how to joinNCT06340568 · EU 2023-507525-42-00
Phase 1Taking people
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Where
Barcelona, Madrid
Age
18 years and over
People
156 worldwide
Run by
Context Therapeutics Inc.
See details and how to joinNCT06515613 · EU 2025-523968-20-00
Phase 3Taking people
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Where
Barcelona, Córdoba, Girona, L'Hospitalet de Llobregat, Madrid, Valencia
Age
18 years and over
People
1,123 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06952504 · EU 2024-519331-42-00
Phase 1/2Taking people
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Where
Barcelona, Logroño, Madrid
Age
18 years and over
People
616 worldwide
Run by
Verastem, Inc.
See details and how to joinNCT07020221
Phase 1Taking people
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Where
Logrono, Madrid, Valencia
Age
18 years and over
People
150 worldwide
Run by
IDEAYA Biosciences
See details and how to joinNCT07503808 · EU 2026-526299-21-00
Phase 1Taking people
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Where
Barcelona, Madrid, Valencia
Age
18 years and over
People
575 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00
Phase 2Taking people
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Where
Barcelona, Las Palmas, Madrid, Málaga, Pamplona, Valencia
Age
18 years and over
People
200 worldwide
Run by
Jazz Pharmaceuticals
See details and how to joinNCT06695845 · EU 2024-516551-41-00
Phase 2Taking people
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Barcelona, L'Hospitalet de Llobregat, Madrid
Age
18 years and over
People
111 worldwide
Run by
Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00
Phase 1Taking people
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Where
Madrid
Age
18 years and over
People
130 worldwide
Run by
Sairopa B.V.
See details and how to joinNCT05856981
Phase 3Taking people
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Where
A Coruña, Barcelona, Girona, Madrid, Málaga, Palma de Mallorca, Pamplona, Seville, Valencia, Zaragoza
Age
18 years and over
People
660 worldwide
Run by
Genmab
See details and how to joinNCT07166094
Phase 1/2Taking people
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Where
Barcelona, Logroño, Madrid, Palma, Zaragoza
Age
18 years and over
People
160 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT07262619 · EU 2026-525248-13-00
Phase 1/2Taking people
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Where
Barcelona, Madrid
Age
18 years and over
People
248 worldwide
Run by
Terremoto Biosciences Inc.
See details and how to joinNCT07109726
Phase 3Taking people
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
Where
A Coruña, Badalona, Barcelona, Girona, Madrid, Murcia, Palma, Sevilla, Valencia
Age
18 years and over
People
710 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT07022483 · EU 2024-519444-33-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Barcelona, Madrid, Málaga, Seville, Valencia
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Sevilla
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 1/2Taking people
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Where
A Coruña, Badalona, Barcelona, Córdoba, Elche, El Palmar, Girona, Lleida, Madrid, Málaga, Pamplona, Pozuelo de Alarcón, Rioja, Sabadell, Santander, Seville, Valencia, Zaragoza
Age
18 years and over
People
542 worldwide
Run by
Artios Pharma Ltd
See details and how to joinNCT04657068
Phase 1/2Taking people
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Where
Barcelona, Logroño, Madrid, Pozuelo de Alarcón
Age
18 years and over
People
245 worldwide
Run by
BioNTech SE
See details and how to joinNCT07186842 · EU 2025-522613-26-00
Phase 1/2Taking people
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona
Age
18 years and over
People
460 worldwide
Run by
AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01
Phase 3Taking people
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Where
A Coruña, Córdoba, Donostia, L'Hospitalet de Llobregat, Madrid, Murcia, Valencia, Zaragoza
Age
18 years and over
People
600 worldwide
Run by
AstraZeneca
See details and how to joinNCT06989112 · EU 2023-508056-19-00
Phase 1Taking people
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Where
Barcelona, Madrid, Pamplona
Age
15 years and over
People
282 worldwide
Run by
Xencor, Inc.
See details and how to joinNCT06276491
Phase 1/2Taking people
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Where
A Coruña, Barcelona, Málaga, Pozuelo de Alarcón, Sant Cugat del Vallès, Sevilla
Age
18 years to 130 years
People
695 worldwide
Run by
AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00
Phase 1/2Taking people
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Where
Barcelona, Madrid, Málaga
Age
18 years to 130 years
People
622 worldwide
Run by
AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
Barcelona, Madrid, Rioja, Valencia
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
Phase 1Taking people
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Where
Barcelona, Logroño, Madrid
Age
18 years and over
People
124 worldwide
Run by
Pliant Therapeutics, Inc.
See details and how to joinNCT06270706
Phase 3Taking people
A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
Where
Barcelona, Madrid
Age
18 years and over
People
134 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to join2025-524160-38-00 · EU 2025-524160-38-00